|Awarded On||February 21, 2019|
|Title||Immunotherapeutic Targeting of SLC45A2 for Treatment of Uveal Melanoma|
|Award Mechanism||Individual Investigator Research Awards for Clinical Translation|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Cassian Yee|
|Cancer Sites||Eye and Orbit, Skin|
Uveal melanoma (UM) is the most common cancer of the eye in adults and, in its advanced stages, is resistant to conventional therapy. Adoptive Cellular Therapy (ACT) is a promising treatment option that uses the patient’s own immune system cells to treat cancer. ACT involves the isolation and expansion of cancer-specific immune cells (T cells) that are infused into patients. These T cells can then go to tumor sites, kill cancer cells, and potentially provide a long-lasting response that protects against recurrence of the cancer. We have developed a form of ACT known as endogenous T cell (ETC) therapy. In ETC, cancer-specific T cells are isolated from the patient’s blood and grown in the lab ...